Àlex Teulé

5.5k total citations
92 papers, 1.5k citations indexed

About

Àlex Teulé is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Àlex Teulé has authored 92 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 51 papers in Epidemiology and 30 papers in Neurology. Recurrent topics in Àlex Teulé's work include Neuroendocrine Tumor Research Advances (50 papers), Lung Cancer Research Studies (40 papers) and Neuroblastoma Research and Treatments (28 papers). Àlex Teulé is often cited by papers focused on Neuroendocrine Tumor Research Advances (50 papers), Lung Cancer Research Studies (40 papers) and Neuroblastoma Research and Treatments (28 papers). Àlex Teulé collaborates with scholars based in Spain, Italy and United Kingdom. Àlex Teulé's co-authors include Rocio García‐Carbonero, Jaume Capdevila, Ramón Salazar, Paula Jiménez‐Fonseca, Daniel Castellano, Joan Brunet, Isabel Sevilla, Conxi Lázaro, Enrique Grande and María Purificación Martínez del Prado and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Àlex Teulé

85 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Àlex Teulé Spain	19	950	811	617	305	279	92	1.5k
Maria A. Kouvaraki United States	14	842 0.9×	770 0.9×	534 0.9×	309 1.0×	117 0.4×	23	1.7k
Harriet Druker Canada	17	478 0.5×	168 0.2×	296 0.5×	553 1.8×	428 1.5×	23	1.6k
Kjell E. Öberg Sweden	19	1.3k 1.4×	1.4k 1.7×	997 1.6×	146 0.5×	46 0.2×	34	2.2k
Karin Bink Germany	13	444 0.5×	236 0.3×	197 0.3×	443 1.5×	126 0.5×	25	1.2k
Lucas Moreno Spain	22	281 0.3×	203 0.3×	642 1.0×	521 1.7×	78 0.3×	93	1.4k
J-Y. Scoazec France	8	1.2k 1.3×	1.3k 1.6×	821 1.3×	260 0.9×	32 0.1×	20	1.6k
Anita Villani Canada	14	353 0.4×	107 0.1×	243 0.4×	392 1.3×	286 1.0×	46	1.2k
Maria Scardoni Italy	15	422 0.4×	266 0.3×	174 0.3×	176 0.6×	62 0.2×	21	824
A. Frilling Germany	21	463 0.5×	356 0.4×	111 0.2×	392 1.3×	150 0.5×	60	1.3k
Mauro Papotti Italy	15	367 0.4×	281 0.3×	153 0.2×	142 0.5×	62 0.2×	24	937

Countries citing papers authored by Àlex Teulé

Since Specialization

Citations

This map shows the geographic impact of Àlex Teulé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Àlex Teulé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Àlex Teulé more than expected).

Fields of papers citing papers by Àlex Teulé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Àlex Teulé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Àlex Teulé. The network helps show where Àlex Teulé may publish in the future.

Co-authorship network of co-authors of Àlex Teulé

This figure shows the co-authorship network connecting the top 25 collaborators of Àlex Teulé. A scholar is included among the top collaborators of Àlex Teulé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Àlex Teulé. Àlex Teulé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). DIGITAL.CSIC (Spanish National Research Council (CSIC)).

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical Cancer Research. 31(22). 4655–4663.

Rofes, Paula, Mireia Menéndez, Àlex Teulé, et al.. (2025). TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate. Genome Medicine. 17(1). 3–3. 1 indexed citations

Guerrero‐Pérez, Fernando, Inmaculada Peiró, J.L. Vercher-Conejero, Àlex Teulé, & Carles Villabona. (2024). Carcinoid crisis: The challenge is still there. Endocrinología Diabetes y Nutrición (English ed ). 71(6). 263–270.

Scarpa, Alfonso, Rita T. Lawlor, Anguraj Sadanandam, et al.. (2024). 1150P Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206). Annals of Oncology. 35. S754–S754. 2 indexed citations

Krogh, Merete, Àlex Teulé, Heinz‐Josef Klümpen, et al.. (2024). 1142O Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206). Annals of Oncology. 35. S750–S750. 1 indexed citations

Pernas, Sònia, Raül Rigo‐Bonnin, Àlex Teulé, et al.. (2024). Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project). Journal of Clinical Medicine. 14(1). 145–145. 1 indexed citations

Martínez, María Carmen Riesco, Jaume Capdevila, Vicente Alonso, et al.. (2024). Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nature Communications. 15(1). 6753–6753. 10 indexed citations

García‐Carbonero, Rocio, Paula Jiménez‐Fonseca, Urbano Anido, et al.. (2024). ¹⁷⁷Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.. Journal of Clinical Oncology. 42(16_suppl). TPS3177–TPS3177.

10.

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2023). Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival. European Journal of Endocrinology. 190(1). 62–74. 6 indexed citations

11.

Navarro, Matilde, Àlex Teulé, Ares Solanes, et al.. (2021). Correction: Dueñas et al. Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers 2020, 12, 3419. Cancers. 13(13). 3104–3104. 1 indexed citations

12.

Grande, Enrique, Cristina Rodríguez‐Antona, Carlos López, et al.. (2021). Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. The Oncologist. 26(11). 941–949. 16 indexed citations

13.

Stradella, Agostina, Jesús Del Valle, Paula Rofes, et al.. (2020). ERCC3, a new ovarian cancer susceptibility gene?. European Journal of Cancer. 141. 1–8. 9 indexed citations

14.

Navarro, Matilde, Àlex Teulé, Ares Solanes, et al.. (2020). Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers. 12(11). 3419–3419. 12 indexed citations

15.

Capdevila, Jaume, Àlex Teulé, Carlos López, et al.. (2020). 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 31. S770–S771. 37 indexed citations

16.

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2020). 1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE). Annals of Oncology. 31. S772–S772. 1 indexed citations

17.

Grande, Enrique, Àlex Teulé, Teresa Alonso‐Gordoa, et al.. (2020). The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). The Oncologist. 25(9). 745–e1265. 24 indexed citations

18.

Guillén‐Ponce, Carmen, Rafael Serrano del Rosal, Àlex Teulé, et al.. (2015). Clinical guideline seom: hereditary colorectal cancer. Clinical & Translational Oncology. 17(12). 962–971. 10 indexed citations

19.

García‐Carbonero, Rocio, Jaume Capdevila, José A. Díaz-Pérez, et al.. (2010). Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of Oncology. 21(9). 1794–1803. 313 indexed citations

20.

Valle, Jesús Del, Lídia Feliubadaló, Marga Nadal, et al.. (2009). Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment. 122(3). 733–743. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact